# Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

> **NCT03066648** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 241 (actual)

## Conditions studied

- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
- Preleukemia
- Bone Marrow Diseases
- Hematologic Diseases
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Decitabine
- **DRUG:** PDR001
- **DRUG:** MBG453
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03066648
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-06
- **Primary completion:** 2023-09-08
- **Final completion:** 2023-09-08
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03066648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03066648, "Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03066648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*